Free tool
FAERS Monitor: Talvey
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761342 or its brand name (Talvey, Talquetamab-Tgvs). Reports on generic versions are filed under their own applications.
Reports
1,489
Serious
924
62% of reports
Hospitalization
282
Death reported
114
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- cytokine release syndrome296
- ageusia140
- skin exfoliation126
- dysgeusia124
- weight decreased121
- dry mouth105
- immune effector cell-associated neurotoxicity syndrome102
- nail disorder95
- pyrexia93
- off label use89
- onychomadesis87
- taste disorder82
- inappropriate schedule of product administration74
- rash68
- dry skin65
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 80 |
| 2024 | 326 |
| 2025 | 608 |
| 2026 | 475 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,670 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| onychomadesisSignal | 87 | 299.0 | 243.3 | 25,018 |
| immune effector cell-associated neurotoxicity syndromeSignal | 102 | 247.5 | 204.9 | 24,375 |
| cytokine release syndromeSignal | 296 | 211.5 | 190.9 | 60,965 |
| nail disorderSignal | 95 | 155.0 | 127.5 | 14,236 |
| ageusiaSignal | 140 | 79.7 | 68.1 | 10,756 |
| taste disorderSignal | 82 | 57.3 | 46.4 | 4,468 |
| dysgeusiaSignal | 124 | 23.6 | 19.9 | 2,668 |
| skin exfoliationSignal | 126 | 21.1 | 17.9 | 2,402 |
| dry mouthSignal | 105 | 18.3 | 15.2 | 1,705 |
| dry skinSignal | 65 | 6.9 | 5.4 | 323 |
| weight decreasedSignal | 121 | 6.1 | 5.2 | 520 |
| inappropriate schedule of product administrationSignal | 74 | 5.8 | 4.6 | 292 |
| pyrexiaSignal | 93 | 3.8 | 3.1 | 192 |
| rashSignal | 68 | 2.2 | 1.7 | 44 |
| off label use | 89 | 1.4 | 1.2 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.